BVF Inc. IL Takes $2.58 Million Position in Vical Incorporated (VICL)
BVF Inc. IL bought a new stake in shares of Vical Incorporated (NASDAQ:VICL) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 1,409,444 shares of the biotechnology company’s stock, valued at approximately $2,579,000. BVF Inc. IL owned approximately 0.08% of Vical at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Armistice Capital LLC bought a new stake in Vical during the 4th quarter valued at $3,660,000. Renaissance Technologies LLC boosted its position in Vical by 17.2% during the 4th quarter. Renaissance Technologies LLC now owns 677,229 shares of the biotechnology company’s stock valued at $1,239,000 after acquiring an additional 99,420 shares in the last quarter. Stonepine Capital Management LLC bought a new stake in Vical during the 4th quarter valued at $1,238,000. Ariel Investments LLC boosted its position in Vical by 9.6% during the 4th quarter. Ariel Investments LLC now owns 637,913 shares of the biotechnology company’s stock valued at $1,167,000 after acquiring an additional 55,669 shares in the last quarter. Finally, New York State Common Retirement Fund boosted its position in Vical by 83.6% during the 2nd quarter. New York State Common Retirement Fund now owns 130,706 shares of the biotechnology company’s stock valued at $354,000 after acquiring an additional 59,504 shares in the last quarter. 55.03% of the stock is currently owned by institutional investors and hedge funds.
In other Vical news, major shareholder Armistice Capital Master Fund acquired 100,000 shares of the firm’s stock in a transaction dated Monday, January 22nd. The stock was purchased at an average price of $1.43 per share, for a total transaction of $143,000.00. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 5.98% of the company’s stock.
Several analysts have issued reports on VICL shares. ValuEngine raised Vical from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd. HC Wainwright reiterated a “buy” rating and set a $5.00 price objective on shares of Vical in a report on Thursday, February 1st. Finally, Zacks Investment Research upgraded Vical from a “sell” rating to a “hold” rating in a report on Saturday, December 2nd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $7.00.
TRADEMARK VIOLATION NOTICE: This story was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this story can be accessed at https://www.thecerbatgem.com/2018/03/11/bvf-inc-il-takes-2-58-million-position-in-vical-incorporated-vicl.html.
Vical Incorporated researches and develops biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of life-threatening diseases. The Company has approximately four active, independent, or partnered development programs in the areas of infectious disease including Phase III clinical trial of ASP0113 for prevention of cytomegalovirus (CMV) reactivation in stem cell transplant recipients and Phase II clinical trial of ASP0113 for prevention of CMV infection in kidney transplant recipients; Phase I/II clinical trial of its therapeutic genital herpes vaccine, designed to reduce viral shedding and genital herpes lesions in herpes simplex virus type 2 (HSV-2) infected patients; an ongoing Phase I program of VL-2397 for invasive fungal infections, and completed preclinical program, with an allowed investigational new drug application (IND) using its CyMVectin prophylactic vaccine formulated with its Vaxfectin adjuvant.
Want to see what other hedge funds are holding VICL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vical Incorporated (NASDAQ:VICL).
Receive News & Ratings for Vical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vical and related companies with MarketBeat.com's FREE daily email newsletter.